Depomed Company Profile (NASDAQ:DEPO)

About Depomed

Depomed logoDepomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company's products include NUCYNTA ER (tapentadol extended release tablets), which is a product for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate; NUCYNTA (tapentadol), which is an immediate release version of tapentadol for the management of moderate to severe acute pain in adults; Gralise, which is a once-daily product for the management of postherpetic neuralgia; CAMBIA, which is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Zipsor, which is a NSAID for the treatment of mild to moderate acute pain, and Lazanda nasal spray, which is used for the management of break through pain in cancer patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: DEPO
  • CUSIP: 24990810
Key Metrics:
  • Previous Close: $16.47
  • 50 Day Moving Average: $18.09
  • 200 Day Moving Average: $20.66
  • 52-Week Range: $12.25 - $27.02
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 13.25
  • P/E Growth: 1.00
  • Market Cap: $971.12M
  • Outstanding Shares: 61,580,000
  • Beta: 1.33
  • Net Margins: -16.93%
  • Return on Equity: -7.49%
  • Return on Assets: -1.73%
  • Debt-to-Equity Ratio: 2.46%
  • Current Ratio: 1.21%
  • Quick Ratio: 1.16%
Additional Links:
Companies Related to Depomed:

Analyst Ratings

Consensus Ratings for Depomed (NASDAQ:DEPO) (?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.45)
Consensus Price Target: $22.36 (41.81% upside)

Analysts' Ratings History for Depomed (NASDAQ:DEPO)
DateFirmActionRatingPrice TargetDetails
2/20/2017MizuhoDowngradeBuy -> NeutralView Rating Details
2/18/2017Roth CapitalSet Price TargetBuy$24.00View Rating Details
1/11/2017Cantor FitzgeraldSet Price TargetHold$23.00View Rating Details
12/12/2016Piper Jaffray CompaniesDowngradeNeutral -> Underweight$17.00 -> $14.00View Rating Details
11/8/2016Leerink SwannSet Price TargetBuy$22.00View Rating Details
10/17/2016Janney Montgomery ScottReiterated RatingBuy$31.00View Rating Details
9/23/2016RBC Capital MarketsReiterated RatingSector Perform$22.00View Rating Details
8/4/2016JMP SecuritiesLower Price TargetMarket Outperform$28.00 -> $22.00View Rating Details
7/11/2016Royal Bank Of CanadaReiterated RatingHoldView Rating Details
3/24/2016Northland SecuritiesInitiated CoverageOutperform$22.00View Rating Details
2/24/2016WallachBeth CapitalLower Price TargetBuy$33.00 -> $27.00View Rating Details
12/3/2015Morgan StanleyInitiated CoverageEqual -> Equal Weight$21.00View Rating Details
(Data available from 2/22/2015 forward)


Earnings History for Depomed (NASDAQ:DEPO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2017Q4 2016$0.36$0.48$123.00 million$123.90 millionViewListenView Earnings Details
11/7/2016Q3$0.35$0.28$127.22 million$111.00 millionViewListenView Earnings Details
8/3/2016Q2$0.26$0.27$118.20 million$116.70 millionViewListenView Earnings Details
5/5/2016Q1$0.17$0.12$106.88 million$104.60 millionViewListenView Earnings Details
2/22/2016Q415$0.29$0.16$110.19 million$111.20 millionViewListenView Earnings Details
11/9/2015Q3$0.19$0.33$101.64 million$105.00 millionViewListenView Earnings Details
7/29/2015Q215($0.45)$0.27$88.33 million$94.30 millionViewListenView Earnings Details
5/11/2015Q115$0.07($0.13)$33.80 million$31.70 millionViewListenView Earnings Details
2/23/2015Q414$0.07$0.21$44.66 million$33.90 millionViewListenView Earnings Details
11/5/2014Q314($0.04)$0.03$41.50 million$51.49 millionViewListenView Earnings Details
8/6/2014Q214($0.08)($0.01)$38.03 million$67.70 millionViewListenView Earnings Details
5/8/2014Q114$0.10($0.01)$53.57 million$76.50 millionViewListenView Earnings Details
3/12/2014Q413($0.21)$0.72$19.06 million$40.60 millionViewListenView Earnings Details
11/5/2013Q313$0.07$0.11$35.55 million$37.50 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.05)$0.01$29.87 million$30.00 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.06)($0.10)$28.93 million$26.20 millionViewListenView Earnings Details
2/20/2013Q4 2012($0.11)($0.07)$26.48 million$26.60 millionViewListenView Earnings Details
11/5/2012Q312($0.11)($0.03)$28.06 million$33.30 millionViewN/AView Earnings Details
8/2/2012($0.22)($0.28)ViewN/AView Earnings Details
5/8/2012($0.24)($0.16)ViewN/AView Earnings Details
3/8/2012($0.31)($0.25)ViewN/AView Earnings Details
11/1/2011($0.23)($0.15)ViewN/AView Earnings Details
8/1/2011($0.05)($0.11)ViewN/AView Earnings Details
5/5/2011$1.05$1.77ViewN/AView Earnings Details
3/3/2011$0.06$0.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Depomed (NASDAQ:DEPO)
Current Year EPS Consensus Estimate: $1.03 EPS
Next Year EPS Consensus Estimate: $1.19 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.22)($0.22)($0.22)
Q2 20161($0.14)($0.14)($0.14)
Q3 20161$0.04$0.04$0.04
Q4 20162($0.37)($0.07)($0.22)
Q1 20171($0.03)($0.03)($0.03)
Q2 20171$0.02$0.02$0.02
Q3 20171$0.02$0.02$0.02
Q4 20171$0.06$0.06$0.06
(Data provided by Zacks Investment Research)


Dividend History for Depomed (NASDAQ:DEPO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Depomed (NASDAQ:DEPO)
Insider Ownership Percentage: 5.12%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/14/2016August J MorettiCFOSell5,000$20.84$104,200.00View SEC Filing  
9/21/2016Thadd M VargasVPSell11,250$25.00$281,250.00View SEC Filing  
8/10/2016August J. MorettiCFOSell5,000$21.40$107,000.00View SEC Filing  
8/10/2016Thadd M VargasVPSell26,290$20.92$549,986.80View SEC Filing  
5/23/2016Thadd M VargasVPSell15,000$20.00$300,000.00View SEC Filing  
5/10/2016Thadd M VargasVPSell15,000$17.64$264,600.00View SEC Filing  
5/9/2016August J MorettiCFOSell5,000$18.00$90,000.00View SEC Filing  
3/11/2016Thadd M VargasVPSell23,000$16.00$368,000.00View SEC Filing  
12/3/2015August J. MorettiCFOSell15,000$18.11$271,650.00View SEC Filing  
6/12/2015Thadd M VargasVPSell5,000$20.70$103,500.00View SEC Filing  
12/2/2014August J MorettiCFOSell5,339$15.85$84,623.15View SEC Filing  
12/2/2014James A SchoeneckCEOSell36,727$15.85$582,122.95View SEC Filing  
12/2/2014Thadd M VargasVPSell8,247$15.85$130,714.95View SEC Filing  
11/19/2014Matthew M GoslingVPSell71,000$15.36$1,090,560.00View SEC Filing  
3/14/2014James SchoeneckCEOSell17,000$14.54$247,180.00View SEC Filing  
3/14/2014Matthew GoslingVPSell21,875$14.74$322,437.50View SEC Filing  
12/2/2013Michael Md SweeneyCMOSell4,270$8.40$35,868.00View SEC Filing  
12/2/2013Thadd VargasVPSell5,296$8.40$44,486.40View SEC Filing  
5/10/2013James A SchoeneckCEOBuy25,000$5.11$127,750.00View SEC Filing  
3/6/2013Karen A DawesDirectorBuy2,000$5.96$11,920.00View SEC Filing  
8/14/2012Peter D StapleDirectorBuy5,000$5.01$25,050.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Depomed (NASDAQ:DEPO)
News IconStock Spotlight: Zooming in on Shares of Depomed, Inc. (NASDAQ:DEPO) - BVN (NASDAQ:DEPO) - February 22 at 5:46 AM logoFed. Circ. Affirms PTAB Nix Of Depomed Drug-Release Patent - Law360 (subscription) (NASDAQ:DEPO) - February 22 at 5:46 AM
News IconDepomed, Inc. (NASDAQ:DEPO) Bearish Target At $26 - Stock Observer (NASDAQ:DEPO) - February 22 at 5:46 AM
News IconStock Price of Depomed, Inc. (DEPO) Decreases -0.72% - Highland Mirror (NASDAQ:DEPO) - February 22 at 5:46 AM logoEarnings Reaction History: Depomed, Inc., 87.5% Follow-Through Indicator, 8.1% Sensitive - Nasdaq (NASDAQ:DEPO) - February 22 at 5:46 AM logoDepomed reports 4Q loss (NASDAQ:DEPO) - February 22 at 5:46 AM logoDepomed Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:DEPO) - February 22 at 5:46 AM logoDepomed Reports 33% Increase in 2016 Net Product Sales (NASDAQ:DEPO) - February 22 at 5:46 AM logoEdited Transcript of DEPO earnings conference call or presentation 21-Feb-17 9:30pm GMT (NASDAQ:DEPO) - February 22 at 5:46 AM logoDepomed beats by $0.12, beats on revenue (NASDAQ:DEPO) - February 21 at 4:20 PM logo3 Companies That Need to Kick Their CEO to the Curb (NASDAQ:DEPO) - February 19 at 3:42 PM
News IconDepomed, Inc. (NASDAQ:DEPO) Daily Sentiment Score At 0 - Stock Observer (NASDAQ:DEPO) - February 19 at 11:06 AM logoDepomed to Report Fourth Quarter Fiscal Year 2016 Financial Results on Tuesday ... (NASDAQ:DEPO) - February 18 at 4:28 PM
News IconDepomed, Inc. (NASDAQ:DEPO) Quarterly EPS At $0.02 - Stock Observer (NASDAQ:DEPO) - February 18 at 8:37 AM logoDrivers of older diesel cars to be charged extra £10 to enter London (NASDAQ:DEPO) - February 17 at 7:38 PM logoDepomed to Report Fourth Quarter Fiscal Year 2016 Financial Results on Tuesday, February 21, 2017 (NASDAQ:DEPO) - February 17 at 7:38 PM
News IconDepomed, Inc. (NASDAQ:DEPO) EPS Estimate At $0.02 - Transcript Daily (NASDAQ:DEPO) - February 16 at 2:29 PM logoMizuho Securities Downgrades DepoMed Inc (DEPO) to Neutral On Dimishing Takeout Conviction - (NASDAQ:DEPO) - February 16 at 2:29 PM logoDepomed, Valeant Pharmaceuticals, Hibbett Sports Downgraded (NASDAQ:DEPO) - February 14 at 5:34 PM logoDepoMed downgraded by Mizuho (NASDAQ:DEPO) - February 14 at 5:34 PM logoForm 5 DEPOMED INC For: Dec 31 Filed by: Schoeneck James A (NASDAQ:DEPO) - February 11 at 9:48 PM
News IconEPS Target Of Depomed, Inc. (NASDAQ:DEPO)Set At $0.02 - Transcript Daily (NASDAQ:DEPO) - February 11 at 4:47 PM
News IconForward Earnings Estimate of Depomed, Inc.(DEPO) - Highland Mirror (NASDAQ:DEPO) - February 11 at 3:15 AM logoForm 5 DEPOMED INC For: Dec 31 Filed by: Schoeneck James A - (NASDAQ:DEPO) - February 11 at 3:15 AM logoGlobal Pain Management Therapeutics Market Segments, Share, Trends 2024 By TMR (NASDAQ:DEPO) - February 9 at 5:12 PM
News IconStock Spotter: Review on Technical Levels for DepoMed Inc. (DEPO) - Benton Bulletin (NASDAQ:DEPO) - February 8 at 10:09 PM
News IconDepomed, Inc. (DEPO): Analyst Rating Changes and PT Levels - Post Analyst (NASDAQ:DEPO) - February 8 at 5:08 PM logoDepomed to Present at Healthcare Conferences in February (NASDAQ:DEPO) - February 8 at 8:54 AM logoBoard Revised as Perrigo Settles With Activist Investor Starboard (NASDAQ:DEPO) - February 7 at 5:50 PM
News IconPatent Expiries of Blockbuster Drugs to Intensify Challenges for Branded Drugs in Global Pain Management Therapeutics Market, states TMR (NASDAQ:DEPO) - February 6 at 4:45 PM
News IconDepomed, Inc. (NASDAQ:DEPO) Price Target At $22.4 - Transcript Daily (NASDAQ:DEPO) - February 6 at 7:23 AM
News IconGlobal Neuropathic Pain Market to Reach a Valuation of US$ 8.3 Billion By 2024 (NASDAQ:DEPO) - February 2 at 5:07 PM
News IconDepomed, Inc. (NASDAQ:DEPO), INSYS Therapeutics, Inc. (NASDAQ:INSY) (NASDAQ:DEPO) - February 2 at 5:07 PM
News IconWhat is the Sell-side Saying About Depomed, Inc. (NASDAQ:DEPO)? - Aiken Advocate (NASDAQ:DEPO) - January 31 at 3:39 AM
News IconConsensus Price Of Depomed, Inc. (NASDAQ:DEPO) Set At $22.4 - Transcript Daily (NASDAQ:DEPO) - January 30 at 10:37 PM
News IconGlobal Pain Management Drugs and Devices Market by Indications & Data Validation, Analysis and Forecast 2022 (NASDAQ:DEPO) - January 30 at 5:37 PM logoAnticonvulsants for Neuropathic Pain Market Professional Survey Report 2017 Comprehensive Analysis, Industry Survey and Forecast 2025 (NASDAQ:DEPO) - January 30 at 10:28 AM
News IconDepomed Inc DEPO Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:DEPO) - January 29 at 4:46 PM
News IconActive Trading Watch on Shares of DepoMed Inc. (DEPO) - Springdale Times (NASDAQ:DEPO) - January 26 at 5:56 PM
News IconDepomed, Inc. (NASDAQ:DEPO) EPS Estimate At $0.11 - Transcript Daily (NASDAQ:DEPO) - January 25 at 10:51 PM
News Icon* Depomed INC (DEPO) Shareholder Penn Capital Management Co INC Trimmed Stake - The Randolph Guide (NASDAQ:DEPO) - January 25 at 10:51 PM
News IconEarnings in Full Force, Analysts Take Aim at Depomed, Inc. (NASDAQ:DEPO) - Wall Street Beacon (NASDAQ:DEPO) - January 25 at 10:51 PM logoDepomed Is Looking Good Either Way - Seeking Alpha (NASDAQ:DEPO) - January 25 at 10:51 PM
News IconDrugmakers manipulate orphan drug rules to create monopolies (NASDAQ:DEPO) - January 24 at 5:22 PM
News IconFirst Week of September 15th Options Trading For Depomed (DEPO) (NASDAQ:DEPO) - January 24 at 5:22 PM
News IconDrugmakers manipulate orphan drug rules to create prized monopolies (NASDAQ:DEPO) - January 22 at 4:39 PM
News IconDownward Trend Continues as Stock Can't Find Its Footing: Depomed, Inc. (NASDAQ:DEPO) - Wall Street Beacon (NASDAQ:DEPO) - January 20 at 4:04 AM logoLundin Law PC, a shareholder rights firm, announces that it is investigating claims against OneMain Holdings, Inc. (NASDAQ:DEPO) - January 19 at 11:03 PM
News IconThe Orphan Drug Act helps pay for rare illness meds. But pharma companies abuse it (NASDAQ:DEPO) - January 19 at 6:00 PM
News IconConstruction of a Claim Term by the PTAB Does Not Negate Indefiniteness (NASDAQ:DEPO) - January 18 at 10:06 PM


What is Depomed's stock symbol?

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

Where is Depomed's stock going? Where will Depomed's stock price be in 2017?

11 brokerages have issued 12 month price targets for Depomed's stock. Their forecasts range from $14.00 to $31.00. On average, they anticipate Depomed's share price to reach $22.36 in the next year.

When will Depomed announce their earnings?

Depomed is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.

What are analysts saying about Depomed stock?

Here are some recent quotes from research analysts about Depomed stock:

  • Cantor Fitzgerald analysts commented, "Management sees aggressive expansion in the pain specialty as PCPs continue to be uncomfortable in prescribing opioids and referring their pain patients. DEPO is currently doing their 12-18 month sales force reorg, with majority of reps focused on pain specialists with Nucynta, Nucynta ER and Gralise." (1/11/2017)

  • Mizuho analysts commented, "We had expected some benefit from stocking in the quarter that did not materialize. Mgmt also lowered its FY:16 revenue guidance from $490-$520M to $480-$505M and tightened its earnings guidance towards the lower end of the prior range (non-GAAP adjusted Earnings are now $95-$105M, down from $95-$115M previously). We were modeling $488.8M in revenues and $84M in net income so the lowered guide is ultimately not that surprising. We will revisit our Buy rating and $23 PT after the earnings call. Product updates: Nucynta/ER sales of $71.9M (26.9% Y/Y growth) missed consensus estimates of $75.5M. Gralise revenues came in at $23.8M relative to $22.1M consensus, growing 13.7% Y/Y. We view this uptick as a sign that mgmt’s efforts to revitalize the brand have been somewhat effective. Zipsor sales of $6.8M (+13.8% Y/Y) beat consensus estimates of $6.4M due to the introduction of a 120 pill bottle (that led to a higher pill count or greater value per prescription). Cambia sales of $7.6M missed consensus estimates of $8.2M but the brand is still growing 11.2% Y/Y. Finally, Lazanda sales of $6.4M beat consensus estimates of $5.8M, and the brand grew 64.9% Y/Y. Activist updates: We expect an investor presentation from Starboard Value during its proxy solicitation period that could drive additional momentum in the stock." (8/4/2016)

Who owns Depomed stock?

Depomed's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (3.64%), Dimensional Fund Advisors LP (2.17%), Oxford Asset Management (1.34%), FMR LLC (1.15%), Alpine Associates Management Inc. (0.93%) and Commonwealth of Pennsylvania Public School Empls Retrmt SYS (0.62%). Company insiders that own Depomed stock include August J Moretti and Thadd M Vargas.

Who sold Depomed stock? Who is selling Depomed stock?

Depomed's stock was sold by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Dimensional Fund Advisors LP, Guggenheim Capital LLC, Highland Capital Management LP, TCW Group Inc., Envestnet Asset Management Inc., Ladenburg Thalmann Financial Services Inc. and Teachers Retirement System of The State of Kentucky. Company insiders that have sold Depomed stock in the last year include August J Moretti and Thadd M Vargas.

Who bought Depomed stock? Who is buying Depomed stock?

Depomed's stock was bought by a variety of institutional investors in the last quarter, including Alpine Associates Management Inc., Commonwealth of Pennsylvania Public School Empls Retrmt SYS, State Street Corp, FMR LLC, Russell Investments Group Ltd., Levin Capital Strategies L.P., Comerica Bank and Glacier Peak Capital LLC.

How do I buy Depomed stock?

Shares of Depomed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Depomed stock cost?

One share of Depomed stock can currently be purchased for approximately $15.77.

Depomed (NASDAQ:DEPO) Chart for Wednesday, February, 22, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Depomed (NASDAQ:DEPO)

Earnings History Chart

Earnings by Quarter for Depomed (NASDAQ:DEPO)

Dividend History Chart

Dividend Payments by Quarter for Depomed (NASDAQ:DEPO)

Last Updated on 2/22/2017 by Staff